Home > Resources > Whitepapers > Biopreservation Best Practices: A Cornerstone in the Supply Chain of Cell-based Therapies – MSC Model Case Study

Biopreservation Best Practices: A Cornerstone in the Supply Chain of Cell-based Therapies – MSC Model Case Study

December 18, 2017

Mesenchymal stromal cells (MSCs) are prime candidates for regenerative medicine and therapeutic applications due to both their potent immuno-modulatory function and a unique ability to proliferate and differentiate into a variety of cell lineages. However, the stresses incurred during bio preservation /stability intervals (non-frozen and cryopreserved), including transit to and from the clinic can render MSCs ineffective and potentially unsafe. Challenges related to the formulation, transportation, distribution and delivery of source material (tissue, blood, marrow) and MSC-based products are important and inter-related components of the supply chain and scale-up. Effective bio preservation can optimize the quality of cell/tissue source material and final cell/tissue products, mitigate the adverse effects of interruptions and unforeseen events throughout the supply chain, as well as support the return to function of MSCs following patient administration.

Spotlight

Medical Regulations Gate - MRG

Welcome to Medical Regulations Gate (MRG). We have brought together a team of highly qualified experts that are associated with a deep and solid level of professionalism to ensure the compliance of your medical devices with Saudi Arabia's medical regulations in order to be placed in the Saudi market.

OTHER WHITEPAPERS

Accelerating Global Access to Gene Therapies: Case Studies from Lowand Middle-Income Countries

whitePaper | October 18, 2022

This document is published by the World Economic Forum as a contribution to a project, insight area or interaction. The findings, interpretations and conclusions expressed herein are a result

Are Nitrosamines aConcern for BiologicManufacturers?

whitePaper | July 12, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.

rFC adoption for bacterial endotoxin testing

whitePaper | December 7, 2022

OVER THE LAST 20 years, the worldwide value of traded pharmaceutical goods has grown six‑fold, from $113 billion in 2000 to $629 billion in 2019.1 Yet amid such robust growth comes risk to supply chain security as manufacturers become increasingly dependent on a global network of suppliers

Bioanalytical Techniques to Advance Biosimilars Development

whitePaper | August 22, 2022

Biosimilar therapies offer more unique approaches to treating patients with serious diseases, such as cancer.

Characterization and identification of glucuronide metabolites

whitePaper | April 21, 2023

This technical note demonstrates the comprehensive characterization and confident identification of glucuronide metabolites from hepatocyte incubations of midazolam. An orthogonal fragmentation mechanism was applied to generate diagnostic fragmentions for confident identification of glucuronide metabolites

Small Molecule Apis Made with Compelling Science

whitePaper | July 17, 2023

As your API demand grows, we grow with you. While we can manufacture volumes in metric tons, we can also go small. If you have a chemistry-based compound and need smaller batches for clinical or commercial use, we can offer the quantities you need at our cGMP small-scale/pilot facilities until you’re ready for full-scale manufacturing.

Spotlight

Medical Regulations Gate - MRG

Events

8th International Conference on Bio-Sensing Technology

Conference

8th International Conference on Bio-Sensing Technology

Conference